Among these, tumor heterogeneity plays a critical role in determining therapeutic outcomes (Table 5):Patients with BRAF wild-type tumors exhibit significantly longer disease-free survival than those with BRAF mutations (P = 0.04), with the former achieving a local objective response rate (ORR) of 80%, compared to 65% in the latter (45). The gene discussed is BRAF; the disease is neoplasm.